سعر نيباسكو بلس 5/12.5 مجم 10 اقراص 2026

Nebasco plus 5/12.5mg 10 tablets: fixed-dose combination of nebivolol 5 mg and hydrochlorothiazide 12.5 mg tablets, 10 per pack (Future pharmaceutical industries (fpi) > tabuk pharmaceutical manufacturing company); for hypertension.

• Essential hypertension in patients whose blood pressure is adequately controlled on nebivolol 5 mg and hydrochlorothiazide 12.5 mg given concurrently.Population: Adultsmedicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC

• Nebivolol (common): headache, dizziness, paraesthesia, dyspnoea, constipation, nausea, diarrhoea, tiredness, oedema; uncommon: bradycardia, heart failure, AV block, hypotension, nightmares, depression, impaired vision, bronchospasm, impotence. Hydrochlorothiazide: electrolyte disturbances, non-melanoma skin cancer (frequency not known), among others listed in the SmPC.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC

• Hypersensitivity to the actives, excipients or other sulphonamide-derived substances; liver insufficiency; anuria or severe renal insufficiency (CrCl <30 ml/min); acute heart failure, cardiogenic shock or decompensation needing IV inotropes; sick sinus syndrome/SA block; 2nd/3rd degree AV block without pacemaker; bradycardia <60 bpm; hypotension (SBP <90 mmHg); severe peripheral circulatory disturbances; history of bronchospasm or asthma; untreated phaeochromocytoma; metabolic acidosis; refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC

• Beta-blocker precautions: discontinue gradually over 1-2 weeks in ischaemic heart disease; reduce dose if resting pulse falls below 50-55 bpm; caution in first-degree AV block, peripheral circulatory disorders, Prinzmetal angina, COPD, psoriasis; may mask hypoglycaemia and hyperthyroid tachycardia; combination with verapamil/diltiazem-type calcium antagonists, class I antiarrhythmics and centrally acting antihypertensives generally not recommended.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC
• Hydrochlorothiazide precautions: electrolyte imbalance (hypokalaemia, hyponatraemia, hypochloraemic alkalosis, hypomagnesaemia, hypercalcaemia) - check electrolytes periodically; may impair glucose tolerance and raise lipids and uric acid (gout); may worsen azotaemia in renal disease; exacerbation of SLE; photosensitivity; positive anti-doping test.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC
• Non-melanoma skin cancer risk increases with cumulative hydrochlorothiazide dose: advise sun protection and regular skin checks. Choroidal effusion, acute myopia and secondary angle-closure glaucoma, and very rare acute respiratory toxicity (ARDS), have been reported: stop treatment if they occur.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC

• LithiumThiazides reduce lithium clearance (toxicity risk); combination not recommended - if necessary monitor serum lithium.medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC
• Class I antiarrhythmics; verapamil/diltiazem-type calcium antagonists; centrally acting antihypertensives (clonidine, methyldopa, moxonidine)Combinations not recommended: potentiated AV-conduction and negative inotropic effects; IV verapamil may cause profound hypotension and AV block; central agents may worsen heart failure and abrupt withdrawal may cause rebound hypertension.medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC
• Potassium-depleting drugs (other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylates)Potentiated hypokalaemia; concomitant use not recommended.medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC

• No adequate data in pregnant women. Nebivolol should not be used during pregnancy unless clearly necessary (beta-blockers reduce placental perfusion: growth retardation, intrauterine death, abortion, early labour; neonatal hypoglycaemia and bradycardia). Hydrochlorothiazide should not be used for essential hypertension in pregnancy except in rare situations where no other treatment can be used.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC
• Use during breastfeeding is not recommended (nebivolol is excreted in animal milk; hydrochlorothiazide is excreted in human milk in small amounts and high-dose thiazides may inhibit lactation); if used, keep doses as low as possible.International label, equivalent formulation · medicines.ie (Irish Pharmaceutical Healthcare Association) - HPRA-authorised SmPC

• Nebivolol: Beta-adrenergic receptor blocker; per the US BYSTOLIC label the antihypertensive mechanism is not definitively established (reduced heart rate and contractility, suppression of renin activity, reduced sympathetic outflow and vasodilation have been proposed).
• Hydrochlorothiazide: Thiazide diuretic that increases renal excretion of sodium and chloride, reducing plasma volume.